

#11  
Patent  
224/042

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Andrew A. Young, *et al.*

Serial No. 08/851,965

Filed: May 6, 1997

For: METHOD FOR PREVENTING  
GASTRITIS USING AMYLIN OR  
AMYLIN AGONISTS



) Group Art Unit 1654

) Examiner CELSA, B.

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(b)

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Your petitioner, AMYLIN PHARMACEUTICALS, INC., having a place of business at  
9373 Town Centre, Suite 250, San Diego, California 92121, represents that it is Assignee and  
owner of the entire interest of U.S. Patent Application No. 08/851,965, filed May 6, 1997.

Adjustment date: 02/16/2000 KPETERSU  
05/20/1999 UAH11 00000038 122475 08851965  
02 FC:248 9373 Town Centre, Suite 250, San Diego, California 92121

CERTIFICATE OF MAILING  
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

EL088591910US  
Express Mail Label No.

May 17, 1999  
Date of Deposit

SD-115534.1

Christine Galbraith

Name of Person Mailing Paper

*Christine Galbraith*  
Signature of Person Mailing Paper

05/20/1999 UAH11 00000038 08851965

02 FC:248 55.00 CH

Your petitioner, AMYLIN PHARMACEUTICALS, INC., hereby disclaims the terminal part equal to the period of abandonment of the statutory term of any patent granted on the instant application. This agreement runs with any patent granted on the instant application and is binding upon any grantee, its successors, or assigns.

The undersigned has reviewed all documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned is an attorney of record and is empowered to act on behalf of the assignee.

Please charge the amount of \$55.00 (Small Entity) for the Terminal Disclaimer Fee to Deposit Account 12-2475. If this amount is incorrect, please charge or credit Deposit Account No. 12-2475 for the appropriate amount.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,  
LYON & LYON



---

Charles S. Berkman  
Registration No. 38,077

633 West Fifth Street  
Suite 4700  
Los Angeles, CA 90071  
(619) 552-8400